C

Corvus Pharmaceuticals

D
CRVS
USD
-0.01
(-0.1135%)
Market Closed
35,824.00
Volume
-0.43
EPS
-
Div Yield
-20.465116
P/E
550,451,272.80
Market Cap
Today
-0.1135%
1 Week
-0.677%
1 Month
58.273%
6 Months
414.620%
12 Months
453.459%
Year To Date
408.671%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
S
SRPT
-2.57
(-2.0903%)
USD
V
VYGR
-0.18
(-2.4759%)
USD
R
RGNX
1.77
(18.7898%)
USD
REGN
REGN
8.505
(1.0417%)
USD
A
ARWR
0.055
(0.2579%)
USD
F
FIXX
(%)
USD
A
ABUS
-0.045
(-1.1905%)
USD
C
CRSP
1.15
(2.2656%)
USD
E
EDIT
-0.11
(-3.3537%)
USD
N
NVTA
(%)
USD

Title:
Corvus Pharmaceuticals

Sector:
Healthcare
Industry:
Biotechnology
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Do you need help or have a question?
Contact Us